IP Library › Granted Patent US 10,322,141

Granted Patent B2

US 10,322,141 · App. 15/300,051 · Granted Jun 18, 2019

Compositions comprising CH848 envelopes and uses thereof

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,322,141
App. No.: 15/300,051
Granted: Jun 18, 2019
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

In certain aspects the invention provides immunogenic compositions comprising CH848 HIV-1 envelopes and their use in methods to induce immune responses in subjects, e.g., human subjects.

Claims (95)

1. A composition comprising a nucleic acid encoding one or more HIV-1 envelope polypeptides, wherein the one or more HIV-1 envelope polypeptides are any one of envelope:

CH0848.3d0949.10.17;

CH0848.3.d0836.10.31;

CH848.3.d0358.80.06;

CH848.3.d1432.5.41; or

CH848.3.d0526.25.02,

wherein CH0848.3d0949.10.17 is a gp140C CH0848.3d0949.10.17 envelope comprising SEQ ID NO:820, or a gp120D11 CH0848.3d0949.10.17 envelope comprising SEQ ID NO:548,

wherein CH0848.3.d0836.10.31 is a gp140C CH0848.3.d0836.10.31 envelope comprising SEQ ID NO:813, or a gp120D11 CH0848.3.d0836.10.31 envelope comprising SEQ ID NO:541,

wherein CH848.3.d0358.80.06 is a gp140C CH848.3.d0358.80.06 envelope comprising SEQ ID NO:702, or a gp120D11 CH848.3.d0358.80.06 envelope comprising SEQ ID NO:430,

wherein CH848.3.d1432.5.41 is a gp140C CH848.3.d1432.5.41 envelope comprising SEQ ID NO:778, or a gp120D11 CH848.3.d1432.5.41 envelope comprising SEQ ID NO:506, and

wherein CH848.3.d0526.25.02 is a gp140C CH848.3.d0526.25.02 envelope comprising SEQ ID NO:718, or a gp120D11 CH848.3.d0526.25.02 envelope comprising SEQ ID NO:446.

2. A composition comprising one or more recombinant HIV-1 envelope polypeptides, wherein the one or more recombinant HIV-1 envelope polypeptides are any one of envelope:

CH0848.3.d0949.10.17,

CH0848.3.d0836.10.31,

CH848.3.d0358.80.06,

CH848.3.d1432.5.41,

CH848.3.d0526.25.02,

wherein CH0848.3d0949.10.17 is a gp140C CH0848.3d0949.10.17 envelope comprising all the consecutive amino acids immediately after signal peptide sequence MRVMGILKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:820, or a gp120D11 CH0848.3d0949.10.17 envelope comprising all the consecutive amino acids immediately after signal peptide sequence MRVMGILKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:548, and

wherein CH0848.3.d0836.10.31 is a gp140C CH0848.3.d0836.10.31 envelope comprising all the consecutive amino acids immediately after signal peptide sequence MRVMGILKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:813, or a gp120D11 CH0848.3.d0836.10.31 envelope comprising all the consecutive amino acids immediately after signal peptide sequence MRVMGILKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:541,

wherein CH848.3.d0358.80.06 is a gp140C CH848.3.d0358.80.06 envelope comprising all the consecutive amino acids immediately after signal peptide sequence MRVMGIPKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:702, or a gp120D11 CH848.3.d0358.80.06 envelope comprising all the consecutive amino acids immediately after signal peptide sequence MRVMGIPKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:430,

wherein CH848.3.d1432.5.41 is a gp140C CH848.3.d1432.5.41 envelope comprising all the consecutive amino acids immediately after signal peptide sequence MRVTGILRNYPQWWIWGILGFWMLMNCNG of SEQ ID NO:778, or a gp120D11 CH848.3.d1432.5.41 envelope comprising all the consecutive amino acids immediately after signal peptide sequence MRVTGILRNYPQWWIWGILGFWMLMNCNG of SEQ ID NO:506, and

wherein CH848.3.d0526.25.02 is a gp140C CH848.3.d0526.25.02 envelope comprising all the consecutive amino acids immediately after signal peptide sequence MKVMGILKNYPQWWIWGILGFWMLMICKG of SEQ ID NO:718, or a gp120D11 CH848.3.d0526.25.02 envelope comprising all the consecutive amino acids immediately after signal peptide sequence MKVMGILKNYPQWWIWGILGFWMLMICKG of SEQ ID NO:446.

3. The composition of claim 1 , wherein the nucleic acid is operably linked to a promoter inserted in an expression vector.

4. The composition of claim 1 further comprising an adjuvant.

5. A method of inducing an immune response in a subject comprising administering a composition comprising one or more HIV-1 envelopes and/or one or more nucleic acids encoding said one or more HIV-1 envelopes, wherein the one or more HIV-1 envelopes are any one of envelope:

CH0848.3.d0949.10.17,

CH0848.3.d0836.10.31,

CH848.3.d0358.80.06,

CH848.3.d1432.5.41, or

CH848.3.d0526.25.02,

wherein CH0848.3d0949.10.17 comprises a gp140C CH0848.3d0949.10.17 envelope encoded by SEQ ID NO:820, or a gp120D11 CH0848.3d0949.10.17 envelope encoded by SEQ ID NO:548,

wherein CH0848.3.d0836.10.31 comprises a gp140C CH0848.3.d0836.10.31 envelope encoded by SEQ ID NO:813, or a gp120D11 CH0848.3.d0836.10.31 envelope encoded by SEQ ID NO:541,

wherein CH848.3.d0358.80.06 comprises a gp140C CH848.3.d0358.80.06 envelope encoded by SEQ ID NO:702, or a gp120D11 CH848.3.d0358.80.06 envelope encoded by SEQ ID NO:430,

wherein CH848.3.d1432.5.41 comprises a gp140C CH848.3.d1432.5.41 envelope encoded by SEQ ID NO:778, or a gp120D11 CH848.3.d1432.5.41 envelope encoded by SEQ ID NO:506,

wherein CH848.3.d0526.25.02 comprises a gp140C CH848.3.d0526.25.02 envelope encoded by SEQ ID NO:718, or a gp120D11 CH848.3.d0526.25.02 envelope encoded by SEQ ID NO:446,

wherein the one or more HIV-1 envelopes are administered as a recombinant polypeptide or a nucleic acid encoding the HIV-1 envelope polypeptide, or any combination thereof, wherein the nucleic acid encoding the HIV-1 envelope polypeptide is operably linked to a promoter, and wherein the composition is administered as a prime or a boost in an amount sufficient to induce an immune response.

6. The method of claim 5 , further comprising administering a second composition comprising one or more HIV-1 envelopes, wherein the one or more HIV-1 envelopes are any one of envelope:

CH0848.3.d0949.10.17,

CH0848.3.d0836.10.31,

CH848.3.d0358.80.06,

CH848.3.d1432.5.41,

CH848.3.d0526.25.02,

wherein CH0848.3d0949.10.17 comprises a gp140C CH0848.3d0949.10.17 envelope encoded by SEQ ID NO:820, or a gp120D11 CH0848.3d0949.10.17 envelope encoded by SEQ ID NO:548,

wherein CH0848.3.d0836.10.31 comprises a gp140C CH0848.3.d0836.10.31 envelope encoded by SEQ ID NO:813, or a gp120D11 CH0848.3.d0836.10.31 envelope encoded by SEQ ID NO:541,

wherein CH848.3.d0358.80.06 comprises a gp140C CH848.3.d0358.80.06 envelope encoded by SEQ ID NO:702, or a gp120D11 CH848.3.d0358.80.06 envelope encoded by SEQ ID NO:430,

wherein CH848.3.d1432.5.41 comprises a gp140C CH848.3.d1432.5.41 envelope encoded by SEQ ID NO:778, or a gp120D11 CH848.3.d1432.5.41 envelope encoded by SEQ ID NO:506,

wherein CH848.3.d0526.25.02 comprises a gp140C CH848.3.d0526.25.02 envelope encoded by SEQ ID NO:718, or a gp120D11 CH848.3.d0526.25.02 envelope encoded by SEQ ID NO:446,

wherein the one or more HIV-1 envelopes are administered as a recombinant protein or a nucleic acid encoding the HIV-1 envelope protein, or any combination thereof, and wherein the nucleic acid encoding the HIV-1 envelope protein is operably linked to a promoter.

7. The method of claim 5 , wherein the composition further comprises an adjuvant.

8. The method of claim 5 , wherein the one or more HIV-1 envelopes are administered as gp120D11 recombinant proteins or gp140C recombinant proteins, wherein gp120D11 CH0848.3d0949.10.17 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MRVMGILKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:548,

the gp120D11 CH0848.3.d0836.10.31 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MRVMGILKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:541,

the gp120D11 CH848.3.d0358.80.06 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MRVMGIPKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:430,

the gp120D11 CH848.3.d1432.5.41 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MRVTGILRNYPQWWIWGILGFWMLMNCNG of SEQ ID NO:506, or

the gp120D11 CH848.3.d0526.25.02 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MKVMGILKNYPQWWIWGILGFWMLMICKG of SEQ ID NO:446,

the gp140C CH0848.3d0949.10.17 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MRVMGILKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:820,

the gp140C CH0848.3.d0836.10.31 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MRVMGILKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:813,

the gp140C CH848.3.d0358.80.06 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MRVMGIPKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:702,

the gp140C CH848.3.d1432.5.41 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MRVTGILRNYPQWWIWGILGFWMLMNCNG of SEQ ID NO:778, or

the gp140C CH848.3.d0526.25.02 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MKVMGILKNYPQWWIWGILGFWMLMICKG of SEQ ID NO:718.

9. The method of claim 6 , wherein the first and/or second composition further comprises an adjuvant.

10. The method of claim 6 , wherein the one or more HIV-1 envelopes are administered as gp120D11 recombinant proteins or gp140C recombinant proteins, wherein

the gp120D11 CH0848.3d0949.10.17 envelope recombinant protein comprises all the consecutive amino acids immediately after signal peptide sequence MRVMGILKNYPQWWIWGILGFWMLMICNG of SEQ ID NO:548,